Discovery of HZS60 as a Novel Brain Penetrant NMDAR/TRPM4 Interaction Interface Inhibitor with Improved Activity and Pharmacokinetic Properties for the Treatment of Cerebral Ischemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Meiling Sun und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate, Brain Ischemia, Neuroprotective Agents, TRPM Cation Channels. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Ningbo Municipality, Key Programme, Ningbo Municipal Bureau of Education.
Abstract (Originalsprache)
The death signaling complex comprising extrasynaptic NMDAR and TRPM4 plays a pivotal role in the pathogenesis of ischemic stroke. Targeting the protein–protein interactions between NMDAR and TRPM4 represents a promising therapeutic strategy for ischemic stroke. Herein, we describe the discovery of a novel series of NMDAR/TRPM4 interaction interface inhibitors aimed at enhancing neuroprotective efficacy and optimizing pharmacokinetic profiles. The representative compound HZS60 displayed significant neuroprotective effects against both NMDA and oxygen-glucose deprivation/reoxygenation-induced ischemic injury in primary neurons. Notably, HZS60 exhibited a favorable pharmacokinetic profile and excellent brain permeability. Furthermore, HZS60 provided effective neuroprotection following brain ischemia and reperfusion injury in vivo . Collectively, these findings underscore the potential of HZS60 as a promising candidate for the development of novel therapeutic strategies for ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China.
- School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China.
- Medical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, China; International Joint Laboratory for Drug Target of Critical Illnesses, School of Pharmacy, Nanjing M…
- State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai 200032, China.
- Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo No.2 Hospital, Ningbo 315000, China.
- The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Huaian 223300, China.
ORCID-Profile: Zhen Wang, Qiuping Xiang, Feng Han, Dongsheng Zhu
Förderung
- Natural Science Foundation of Ningbo Municipality
- Key Programme
- Ningbo Municipal Bureau of Education
- National Natural Science Foundation of China
- Ningbo Life and Health Industry Research Institute, Chinese Academy of Sciences
- Ningbo Second Hospital
Zitieren
APA
Sun, M., Wang, L., Cao, Q., Wang, X., Zhang, Y., Guo, M., Chen, J., Ma, Y., Niu, L., Zhang, Y., Hu, M., Gu, M., Zhu, Z., Yao, X., Yao, J., Zhao, C., Wu, J., Liu, X., Lu, Y., …, & Zhu, D. (2025). Discovery of HZS60 as a Novel Brain Penetrant NMDAR/TRPM4 Interaction Interface Inhibitor with Improved Activity and Pharmacokinetic Properties for the Treatment of Cerebral Ischemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02772
Vancouver
Sun M, Wang L, Cao Q, Wang X, Zhang Y, Guo M, et al. Discovery of HZS60 as a Novel Brain Penetrant NMDAR/TRPM4 Interaction Interface Inhibitor with Improved Activity and Pharmacokinetic Properties for the Treatment of Cerebral Ischemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02772
BibTeX
@article{Sun2025,
author = {Sun, Meiling and Wang, Lin and Cao, Qiaofeng and Wang, Xuechun and Zhang, Ying and Guo, Manyu and Chen, Jie and Ma, Yuchen and Niu, Le and Zhang, Yanping and Hu, Mengdie and Gu, Mengli and Zhu, Zhihui and Yao, Xinyi and Yao, Junchen and Zhao, Chen and Wu, Jin and Liu, Xiuxiu and Lu, Yingmei and Wang, Zhen and Xiang, Qiuping and Han, Feng and Zhu, Dongsheng},
title = {Discovery of HZS60 as a Novel Brain Penetrant NMDAR/TRPM4 Interaction Interface Inhibitor with Improved Activity and Pharmacokinetic Properties for the Treatment of Cerebral Ischemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02772}
}
EUVIMED